Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomic profiling of ovarian clear cell carcinoma reveals heterogeneity in OXPHOS and EMT gradients.

Nature communications·2026
Same author

Uncoupling anatomical barriers from radiotherapy toxicity: a two-part hurdle analysis of sexual function in gynecologic cancer.

The journal of sexual medicine·2026
Same author

Development of a novel multimodal deep learning approach to improve diagnostic precision in ovarian cancer.

Briefings in bioinformatics·2026
Same author

A potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer.

Journal of ovarian research·2026
Same author

Survival outcomes and time toxicity of Sandwich versus Sequential chemoradiation in Stage III endometrial cancer: A real-world study stratified by molecular classification.

Gynecologic oncology·2026
Same author

Association of homologous recombination repair gene mutation with clinical prognosis in histological subtypes of epithelial ovarian cancer patients.

Journal of gynecologic oncology·2025

Related Experiment Video

Updated: Jan 7, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K

BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy.

Ming-Cheng Chang1, Wan-Chi Lee1, Yi-Jou Tai2,3

  • 1Department of Isotope Application Research, National Atomic Research Institute, No. 1000, Wenhua Rd., Longtan Dist., Taoyuan City 325207, Taiwan.

Pharmaceuticals (Basel, Switzerland)
|December 31, 2025
PubMed
Summary

B and T lymphocyte attenuator (BTLA) is a key regulator of immune responses. Targeting BTLA offers a promising strategy to overcome immune evasion in cancers resistant to current immunotherapies.

Keywords:
B and T lymphocyte attenuatorBTLAcancer immunotherapyclinical applicationsimmune checkpointoncology

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

Related Experiment Videos

Last Updated: Jan 7, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.4K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.0K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Signaling

Background:

  • B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor with dual roles in immune activation and tolerance.
  • BTLA's bidirectional interaction with HVEM creates a complex signaling network influencing the tumor microenvironment.
  • Altered BTLA expression correlates with tumor immune evasion and poor patient prognosis in various cancers.

Purpose of the Study:

  • To provide a comprehensive review of BTLA's structure, signaling, and function in tumor immunity.
  • To discuss the therapeutic potential of targeting BTLA in cancer treatment.
  • To explore challenges and future directions for BTLA-targeted therapies.

Main Methods:

  • Literature review of BTLA's role in cancer immunity.
  • Analysis of BTLA's molecular interactions and signaling pathways.
  • Synthesis of current research on BTLA-targeted therapeutic strategies.

Main Results:

  • BTLA's unique properties distinguish it from other immune checkpoints like PD-1 and CTLA-4.
  • Dysregulated BTLA contributes to tumor immune escape, making it a target for novel therapies.
  • BTLA modulation is a potential strategy for enhancing immunotherapy in treatment-resistant tumors.

Conclusions:

  • BTLA is a significant emerging target for cancer immunotherapy, especially for tumors unresponsive to existing treatments.
  • Further research into BTLA's mechanisms and targeted therapies is crucial for improving cancer treatment outcomes.
  • Leveraging BTLA modulation holds promise for advancing cancer immunotherapy.